Biotechnology Assets Statistics

Total Valuation

Biotechnology Assets has a market cap or net worth of EUR 18.78 million. The enterprise value is 20.44 million.

Market Cap	18.78M
Enterprise Value	20.44M

Important Dates

The next estimated earnings date is Friday, April 4, 2025.

Earnings Date	Apr 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Biotechnology Assets has 64.32 million shares outstanding. The number of shares has increased by 10.39% in one year.

Current Share Class	n/a
Shares Outstanding	64.32M
Shares Change (YoY)	+10.39%
Shares Change (QoQ)	+10.39%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	36.37M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.52
PB Ratio	2.52
P/TBV Ratio	4.11
P/FCF Ratio	20.33
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-6.70
EV / Sales	6.06
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	22.12

Financial Position

The company has a current ratio of 0.85, with a Debt / Equity ratio of 0.34.

Current Ratio	0.85
Quick Ratio	0.85
Debt / Equity	0.34
Debt / EBITDA	n/a
Debt / FCF	2.68
Interest Coverage	-7.11

Financial Efficiency

Return on equity (ROE) is -40.78% and return on invested capital (ROIC) is -11.40%.

Return on Equity (ROE)	-40.78%
Return on Assets (ROA)	-7.56%
Return on Capital (ROIC)	-11.40%
Revenue Per Employee	88,762
Profits Per Employee	-80,323
Employee Count	37
Asset Turnover	0.21
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -23.22% in the last 52 weeks. The beta is 1.39, so Biotechnology Assets's price volatility has been higher than the market average.

Beta (5Y)	1.39
52-Week Price Change	-23.22%
50-Day Moving Average	0.30
200-Day Moving Average	0.33
Relative Strength Index (RSI)	41.77
Average Volume (20 Days)	156,240

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Biotechnology Assets had revenue of EUR 3.37 million and -3.05 million in losses. Loss per share was -0.05.

Revenue	3.37M
Gross Profit	2.90M
Operating Income	-1.96M
Pretax Income	-2.32M
Net Income	-3.05M
EBITDA	-1.72M
EBIT	-1.96M
Loss Per Share	-0.05

Full Income Statement

Balance Sheet

The company has 672,452 in cash and 2.48 million in debt, giving a net cash position of -1.81 million or -0.03 per share.

Cash & Cash Equivalents	672,452
Total Debt	2.48M
Net Cash	-1.81M
Net Cash Per Share	-0.03
Equity (Book Value)	7.23M
Book Value Per Share	0.12
Working Capital	-512,668

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 993,395 and capital expenditures -69,454, giving a free cash flow of 923,941.

Operating Cash Flow	993,395
Capital Expenditures	-69,454
Free Cash Flow	923,941
FCF Per Share	0.01

Full Cash Flow Statement

Margins

Gross margin is 86.10%, with operating and profit margins of -57.98% and -90.49%.

Gross Margin	86.10%
Operating Margin	-57.98%
Pretax Margin	-68.88%
Profit Margin	-90.49%
EBITDA Margin	-51.03%
EBIT Margin	-57.98%
FCF Margin	27.39%

Dividends & Yields

Biotechnology Assets does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.39%
Shareholder Yield	-10.39%
Earnings Yield	-16.40%
FCF Yield	4.92%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biotechnology Assets has an Altman Z-Score of -7.47. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-7.47
Piotroski F-Score	n/a